World Migraine and Headache Awareness Month: Beyond headache recognition

Notice: Blog posts are not subject to review by MedLink Neurology’s Editorial Board. MedLink acknowledges using artificial intelligence to assist in the creation of blog posts.

June is recognized internationally as World Migraine and Headache Awareness Month, an observance promoted by multiple headache advocacy organizations, professional societies, and patient support groups. Campaigns led by organizations such as the National Headache Foundation, American Headache Society, and the Migraine Research Foundation aim to increase public and professional understanding of migraine as a serious neurologic disease rather than simply a “bad headache.”

Awareness efforts typically focus on:

• Reducing stigma surrounding migraine
• Encouraging earlier diagnosis
• Improving access to specialty care
• Expanding insurance coverage for preventive therapies
• Promoting workplace and school accommodations
• Supporting headache research funding

The annual observance also highlights the persistent gap between migraine prevalence and access to effective treatment.

Migraine as a major cause of disability

Migraine remains one of the leading causes of years lived with disability worldwide, particularly among younger and middle-aged adults. The disorder disproportionately affects women during peak working and caregiving years and may substantially impair educational attainment, employment stability, and quality of life.

For many patients, disability extends far beyond episodic pain. Chronic migraine may interfere with:

• Sustained concentration
• Occupational productivity
• School attendance
• Parenting and caregiving responsibilities
• Social participation

Patients may also experience:

• Cognitive dysfunction
• Vestibular symptoms
• Interictal anticipatory anxiety
• Medication overuse headache
• Comorbid depression, anxiety, and sleep disorders

The cumulative effects of recurrent migraine attacks often lead to substantial economic and psychosocial burden.

Chronic migraine, defined as headache occurring on 15 or more days monthly for more than 3 months with migraine features on at least 8 days monthly, is associated with especially high healthcare utilization and functional impairment.

The problem of underdiagnosis

Despite migraine’s prevalence, many patients remain undiagnosed or improperly treated for years.

Migraine is commonly misattributed to:

• “Sinus headache”
• Stress-related headache
• Cervical pain syndromes
• Refractory tension-type headache

Some patients receive repeated antibiotic courses or opioid prescriptions before migraine is appropriately recognized.

Several factors contribute to underdiagnosis in primary care settings:

1. Variable symptom presentation
2. Limited formal headache training
3. Underrecognition of migraine aura
4. Failure to apply standardized diagnostic criteria
5. Symptom overlap with vestibular and autonomic disorders

Patients may also underreport symptoms such as sensory sensitivity or cognitive dysfunction because they do not recognize them as part of migraine.

As a result, neurologists frequently encounter patients only after prolonged disability and unsuccessful treatment attempts.

Review key aspects of assessing and diagnosing migraine in the clinical setting in Migraine: clinical aspects.

Awareness campaigns and advocacy goals

Migraine awareness initiatives increasingly emphasize that migraine is a biologically based neurologic disorder with substantial public health implications.

Common awareness activities include:

• Public education campaigns
• Social media outreach
• Workplace advocacy programs
• Fundraising for research
• Educational webinars and patient conferences
• Promotion of headache screening tools

Advocacy organizations also work to address stigma. Many patients report that migraine symptoms are minimized by employers, schools, family members, and even healthcare professionals.

This issue is particularly important because migraine often affects individuals during otherwise healthy and productive years, yet outward signs of illness may not be visible between attacks.

Awareness campaigns, therefore, attempt to improve recognition of migraine-related disability while encouraging earlier referral and evidence-based treatment.

Emerging therapies and persistent barriers

The emergence of calcitonin gene-related peptide-targeted therapies has substantially changed migraine management over the past decade. Monoclonal antibodies and small-molecule CGRP receptor antagonists now offer migraine-specific preventive and acute treatment options for many patients who previously failed traditional therapies.

These agents generally provide:

• Improved tolerability
• Simplified dosing schedules
• Reduced systemic adverse effects
• Migraine-specific mechanisms of action

However, substantial barriers remain. Insurance authorization requirements, high medication costs, and limited access to specialists continue to restrict treatment availability for many patients.

Awareness campaigns increasingly focus not only on disease recognition but also on improving equitable access to modern therapies.

For an updated overview of migraine treatment, including pharmacologic, nonpharmacologic, and neuromodulation strategies based on recent evidence and evolving clinical guidelines, see Migraine treatment. For further discussion of Anti-CGRP monoclonal antibodies, see Anti-CGRP monoclonal antibodies for prevention of migraine.

The neurologist’s role

Neurologists remain central to migraine diagnosis, education, and management. Beyond treating refractory cases, neurologists help:

• Differentiate migraine from secondary headache disorders
• Reduce unnecessary imaging and opioid exposure
• Educate primary care clinicians
• Interpret complex aura presentations
• Identify medication overuse headache
• Guide evidence-based preventive therapy

As World Migraine and Headache Awareness Month continues each June, its broader message extends beyond symptom recognition alone. The campaign reflects an ongoing effort to frame migraine as a serious neurologic disorder deserving of timely diagnosis, evidence-based treatment, workplace accommodation, and continued research investment.

References

Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 2021;61(7):1021-39. PMID 34160823

Ashina M. Migraine. N Engl J Med 2020;383(19):1866-76. PMID 33211930

Dodick DW. Migraine. Lancet 2018;391(10127):1315-30. PMID 29523342

GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016. Lancet Neurol 2018;17(11):954-76. PMID 30353868

Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 2013;53(1):81-92. PMID 23078241

Are you interested in contributing a post or becoming a guest blogger for MedLink? Contact us at editorial@medlink.com.